Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H18FN3O2 |
Molecular Weight | 303.332 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=Nc1ccc(cc1N)NCc2ccc(cc2)F)O
InChI
InChIKey=PCOBBVZJEWWZFR-UHFFFAOYSA-N
InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)
Molecular Formula | C16H18FN3O2 |
Molecular Weight | 303.332 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21686305; https://www.ncbi.nlm.nih.gov/pubmed/?term=22221318
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21686305; https://www.ncbi.nlm.nih.gov/pubmed/?term=22221318
Ezogabine (U.S. adopted name) or retigabine (international nonproprietary name) is one of a family of aminopyrroles with anticonvulsant activity. It is used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The drug was approved by the European Medicines Agency under the trade name Trobalt and by the United States Food and Drug Administration (FDA), under the trade name Potiga. The mechanism by which ezogabine exerts its therapeutic effects has not been fully elucidated. In vitro studies indicate that ezogabine enhances transmembrane potassium currents mediated by the KCNQ (Kv7.2 to 7.5) family of ion channels. By activating KCNQ channels, ezogabine is thought to stabilize the resting membrane potential and reduce brain excitability. This mechanism of action is unique among antiepileptic drugs, and may hold promise for the treatment of other neurologic conditions, including migraine, tinnitus and neuropathic pain. In vitro studies suggest that ezogabine may also exert therapeutic effects through augmentation of GABA-mediated currents.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=22221318
Curator's Comment:: Ezogabine can cross the blood–brain barrier and is not subject to P-glycoprotein active transport across this barrier, free brain concentrations will closely follow free plasma concentrations.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363063 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=21686305 |
1.6 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | POTIGA Approved UseIndicated as adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments and for whom the benefits outweigh the risk of retinal abnormalities and potential decline in visual acuity Launch Date1.30766406E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
414 ng/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
498 ng/mL |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
551.9 ng/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
561 ng/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
819 ng/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
842 ng/mL |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
993 ng/mL |
250 mg 2 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
978 ng/mL |
200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
728.8 ng/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
938.7 ng/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1831 ng × h/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1914 ng × h/mL |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3972.5 ng × h/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
4393.8 ng × h/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5134 ng × h/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
5136 ng × h/mL |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
5184 ng × h/mL |
250 mg 2 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
5279 ng × h/mL |
200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7355.9 ng × h/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7895.9 ng × h/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.4 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.2 h |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.4 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.9 h |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
6.8 h |
250 mg 2 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7 h |
200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.57 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.28 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EZOGABINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
Doses
Dose | Population | Adverse events |
---|---|---|
350 mg 3 times / day multiple, oral Recommended Dose: 350 mg, 3 times / day Route: oral Route: multiple Dose: 350 mg, 3 times / day Sources: |
unhealthy, 30 years n = 2 Health Status: unhealthy Condition: epilepsy Age Group: 30 years Sex: F Population Size: 2 Sources: |
Disc. AE: Mucocutaneous disorder... AEs leading to discontinuation/dose reduction: Mucocutaneous disorder (2 patients) Sources: |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Disc. AE: Dizziness, Confusional state... Other AEs: Urinary tract infection, Influenza... AEs leading to discontinuation/dose reduction: Dizziness (9.2%) Other AEs:Confusional state (6.5%) Ataxia (2.6%) Somnolence (3.9%) Dysarthria (2.6%) Headache (1.3%) Fatigue (3.3%) Vision blurred (1.3%) Tremor (2.6%) Nausea (2.6%) Speech disorder (0.7%) Memory impairment (0.7%) Diplopia (2%) Gait disturbance (1.3%) Balance disorder (0.7%) Vomiting (1.3%) Anxiety (1.3%) Disturbance in attention (2%) Urinary tract infection (11.8%) Sources: Influenza (7.8%) Constipation (5.9%) Urinary hesitation (5.9%) Dysuria (5.2%) Disorientation (5.2%) |
50 mg 3 times / day multiple, oral (starting) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, 48 years n = 1 Health Status: unhealthy Condition: epilepsy Age Group: 48 years Sex: F Population Size: 1 Sources: |
Disc. AE: Maculopathy... AEs leading to discontinuation/dose reduction: Maculopathy (1 patient) Sources: |
600 mg 1 times / day multiple, oral Recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, adult n = 813 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 813 Sources: |
Disc. AE: Dizziness, Confusional state... AEs leading to discontinuation/dose reduction: Dizziness (6%) Sources: Confusional state (4%) Fatigue (3%) Somnolence (3%) |
2500 mg 1 times / day multiple, oral Overdose Dose: 2500 mg, 1 times / day Route: oral Route: multiple Dose: 2500 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: epilepsy Sources: |
Other AEs: Agitation, Aggressive behavior... Other AEs: Agitation Sources: Aggressive behavior Irritability |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Mucocutaneous disorder | 2 patients Disc. AE |
350 mg 3 times / day multiple, oral Recommended Dose: 350 mg, 3 times / day Route: oral Route: multiple Dose: 350 mg, 3 times / day Sources: |
unhealthy, 30 years n = 2 Health Status: unhealthy Condition: epilepsy Age Group: 30 years Sex: F Population Size: 2 Sources: |
Balance disorder | 0.7% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Memory impairment | 0.7% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Speech disorder | 0.7% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Anxiety | 1.3% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Gait disturbance | 1.3% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Headache | 1.3% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Vision blurred | 1.3% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Vomiting | 1.3% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Urinary tract infection | 11.8% | 1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Diplopia | 2% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Disturbance in attention | 2% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Ataxia | 2.6% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Dysarthria | 2.6% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Nausea | 2.6% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Tremor | 2.6% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Fatigue | 3.3% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Somnolence | 3.9% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Disorientation | 5.2% | 1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Dysuria | 5.2% | 1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Constipation | 5.9% | 1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Urinary hesitation | 5.9% | 1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Confusional state | 6.5% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Influenza | 7.8% | 1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Dizziness | 9.2% Disc. AE |
1200 mg 1 times / day multiple, oral Highest studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: |
unhealthy, 37.7 years (range: 18 –71 years) n = 153 Health Status: unhealthy Condition: drug-resistant partial epilepsy Age Group: 37.7 years (range: 18 –71 years) Sex: M+F Population Size: 153 Sources: |
Maculopathy | 1 patient Disc. AE |
50 mg 3 times / day multiple, oral (starting) Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, 48 years n = 1 Health Status: unhealthy Condition: epilepsy Age Group: 48 years Sex: F Population Size: 1 Sources: |
Fatigue | 3% Disc. AE |
600 mg 1 times / day multiple, oral Recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, adult n = 813 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 813 Sources: |
Somnolence | 3% Disc. AE |
600 mg 1 times / day multiple, oral Recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, adult n = 813 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 813 Sources: |
Confusional state | 4% Disc. AE |
600 mg 1 times / day multiple, oral Recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, adult n = 813 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 813 Sources: |
Dizziness | 6% Disc. AE |
600 mg 1 times / day multiple, oral Recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, adult n = 813 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 813 Sources: |
Aggressive behavior | 2500 mg 1 times / day multiple, oral Overdose Dose: 2500 mg, 1 times / day Route: oral Route: multiple Dose: 2500 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: epilepsy Sources: |
|
Agitation | 2500 mg 1 times / day multiple, oral Overdose Dose: 2500 mg, 1 times / day Route: oral Route: multiple Dose: 2500 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: epilepsy Sources: |
|
Irritability | 2500 mg 1 times / day multiple, oral Overdose Dose: 2500 mg, 1 times / day Route: oral Route: multiple Dose: 2500 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: epilepsy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf#page=149 Page: 149.0 |
likely | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf#page=177 Page: 177.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf#page=177 Page: 177.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf#page=177 Page: 177.0 |
no | |||
Page: 15.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf#page=177 Page: 177.0 |
no | |||
Page: 15.0 |
no |
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000PharmR.pdf#page=19 Page: 19.0 |
PubMed
Title | Date | PubMed |
---|---|---|
A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modulators in mammalian cells. | 2004 Dec |
|
Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats. | 2004 Nov |
|
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). | 2004 Sep-Oct |
|
Ion channel defects in idiopathic epilepsies. | 2005 |
|
Voltage gated ion channels: targets for anticonvulsant drugs. | 2005 |
|
Effects of M-current modulators on the excitability of immature rat spinal sensory and motor neurones. | 2005 Dec |
|
Effects of retigabine on the neurodegeneration and extracellular glutamate changes induced by 4-aminopyridine in rat hippocampus in vivo. | 2005 Dec |
|
Gateways to clinical trials. | 2005 Jan-Feb |
|
Presynaptic inhibition of transmitter release from rat sympathetic neurons by bradykinin. | 2005 Jun |
|
The KCNQ5 potassium channel from mouse: a broadly expressed M-current like potassium channel modulated by zinc, pH, and volume changes. | 2005 Sep 13 |
|
Retigabine: bending potassium channels to our will. | 2005 Sep-Oct |
|
[Voltage-activated potassium channels of the inhibitory interneurons of the hippocampus in culture]. | 2006 |
|
Retigabine: in partial seizures. | 2006 |
|
Gateways to clinical trials. | 2006 Apr |
|
Ionic mechanisms of autorhythmic firing in rat cerebellar Golgi cells. | 2006 Aug 1 |
|
New antiepileptic drugs that are second generation to existing antiepileptic drugs. | 2006 Jun |
|
KCNQ/Kv7 channel regulation of hippocampal gamma-frequency firing in the absence of synaptic transmission. | 2006 May |
|
The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine. | 2006 May-Jun |
|
Antidystonic effects of Kv7 (KCNQ) channel openers in the dt sz mutant, an animal model of primary paroxysmal dystonia. | 2006 Nov |
|
The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. | 2006 Nov |
|
Somatodendritic Kv7/KCNQ/M channels control interspike interval in hippocampal interneurons. | 2006 Nov 22 |
|
An exploratory open trial on safety and efficacy of the anticonvulsant retigabine in acute manic patients. | 2006 Oct |
|
Kv7/KCNQ/M-channels in rat glutamatergic hippocampal axons and their role in regulation of excitability and transmitter release. | 2006 Oct 1 |
|
Retigabine-induced population primary afferent hyperpolarisation in vitro. | 2006 Sep |
|
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. | 2007 Apr 10 |
|
Recruitment of apical dendritic T-type Ca2+ channels by backpropagating spikes underlies de novo intrinsic bursting in hippocampal epileptogenesis. | 2007 Apr 15 |
|
Inactivation as a new regulatory mechanism for neuronal Kv7 channels. | 2007 Apr 15 |
|
A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new diphenylamine derivatives. | 2007 Dec 26 |
|
Kv7.2-7.5 voltage-gated potassium channel (KCNQ2-5) opener, retigabine, reduces capsaicin-induced visceral pain in mice. | 2007 Feb 14 |
|
Retigabine. | 2007 Jan |
|
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). | 2007 Jan |
|
Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels. | 2007 May |
|
Phenytoin- and carbamazepine-resistant spontaneous bursting in rat entorhinal cortex is blocked by retigabine in vitro. | 2007 May |
|
Peripheral nerve hyperexcitability due to dominant-negative KCNQ2 mutations. | 2007 Nov 27 |
|
Retigabine: has the orphan found a home? | 2007 Nov-Dec |
|
Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety. | 2007 Oct |
|
The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine. | 2007 Sep 10 |
|
The effectiveness of anticonvulsants in psychiatric disorders. | 2008 |
|
Nervous system KV7 disorders: breakdown of a subthreshold brake. | 2008 Apr 1 |
|
The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease. | 2008 Feb |
|
The KCNQ/M-current modulates arterial baroreceptor function at the sensory terminal in rats. | 2008 Feb 1 |
|
Effect of the new antiepileptic drug retigabine in a rodent model of mania. | 2008 Jan |
|
Expression profile and characterisation of a truncated KCNQ5 splice variant. | 2008 Jul 11 |
|
Retigabine reduces the excitability of unmyelinated peripheral human axons. | 2008 Jun |
|
Gateways to clinical trials. | 2008 Mar |
|
Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study. | 2008 Oct |
|
Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents. | 2008 Sep |
|
Retigabine, the specific KCNQ channel opener, blocks ectopic discharges in axotomized sensory fibres. | 2008 Sep 15 |
|
Expression and function of K(v)7 channels in murine myometrium throughout oestrous cycle. | 2009 Mar |
Sample Use Guides
Potiga should be given orally in 3 equally divided doses daily, with or without food. The initial dosage should be 100 mg 3 times daily (300 mg per day) and should be increased gradually at weekly intervals by no more than 50 mg 3 times daily (increase in the daily dose of no more than 150 mg per day) up to a maintenance dosage of 200 mg to 400 mg 3 times daily (600 mg to 1,200 mg per day), based on individual patient response and tolerability.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11378159
KCNQ4 channels, stably expressed in HEK293 cells, were activated by retigabine (ezogabine) in a reversible and concentration-dependent manner in the concentration range 0.1-10 uM. Retigabine shifted the KCNQ4 channel activation curves towards more negative potentials by about 10 mV.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:37:48 UTC 2021
by
admin
on
Fri Jun 25 21:37:48 UTC 2021
|
Record UNII |
12G01I6BBU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000182729
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
||
|
DEA NO. |
2779
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
TROBALT (AUTHORIZED: EPILEPSY)
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
||
|
FDA ORPHAN DRUG |
639118
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
||
|
WHO-VATC |
QN03AX21
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
||
|
NCI_THESAURUS |
C264
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
||
|
WHO-ATC |
N03AX21
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
||
|
LIVERTOX |
397
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
121892
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | |||
|
M5229
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | Merck Index | ||
|
8171
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | |||
|
Retigabine
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | |||
|
2601
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | |||
|
Ezogabine
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | |||
|
7545
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | |||
|
150812-12-7
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | |||
|
4181
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | |||
|
C72839
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | |||
|
SUB10291MIG
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | |||
|
1112990
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | RxNorm | ||
|
N0000182728
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | Potassium Channel Openers [MoA] | ||
|
150812-12-7
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | |||
|
DB04953
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | |||
|
CHEMBL41355
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY | |||
|
12G01I6BBU
Created by
admin on Fri Jun 25 21:37:48 UTC 2021 , Edited by admin on Fri Jun 25 21:37:48 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
EXCRETED UNCHANGED |
URINE
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
|
|||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
INTRAVENOUS ADMINISTRATION |
|
||